- Report
- April 2025
- 175 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- October 2024
- 182 Pages
Global
From €3227EUR$3,545USD£2,741GBP
€3585EUR$3,939USD£3,045GBP
- Report
- April 2025
- 62 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- May 2024
- 137 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- May 2024
- 138 Pages
Global
From €5915EUR$6,499USD£5,024GBP
- Report
- August 2024
- 114 Pages
Global
From €7236EUR$7,950USD£6,146GBP
- Report
- June 2024
- 105 Pages
Global
From €13648EUR$14,995USD£11,592GBP
- Report
- August 2022
- 120 Pages
Global
From €4323EUR$4,750USD£3,672GBP
- Report
- April 2018
- 195 Pages
Global
From €13648EUR$14,995USD£11,592GBP
- Report
- March 2021
- 48 Pages
Global
€20024EUR$22,000USD£17,007GBP
The Evenity market is a subset of the Musculoskeletal Disorders Drugs market, which focuses on treatments for conditions such as osteoporosis, rheumatoid arthritis, and ankylosing spondylitis. Evenity is a biologic drug used to treat osteoporosis in postmenopausal women, and is designed to reduce the risk of fractures. It is administered as an intravenous infusion, and is typically used in combination with other treatments.
The Evenity market is highly competitive, with a number of companies offering similar treatments. These include Amgen, Eli Lilly, Merck, Novartis, and Pfizer. Each company has its own unique approach to the treatment of musculoskeletal disorders, and offers a range of products and services to meet the needs of patients. Show Less Read more